0
Kura Oncology, Inc. Banner Image

Kura Oncology, Inc. has reached its limit for free report views

Work for Kura Oncology, Inc.? Upgrade Your Profile and unlock all your annual reports.

Kura Oncology, Inc.

  • Ticker KURA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Kura Oncology, Inc. Logo Image
  • 51-200 Employees
  • Based in San Diego, California
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely toMore benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2A(MLL) protein-protein interaction currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia.
Kura Oncology, Inc.

Most Recent Annual Report

Kura Oncology, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Kura Oncology, Inc. has reached its limit for free report views.